Graybug Vision, Inc. (GRAY) Research

Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical development phase, dedicated to creating treatments for conditions affecting the eye's retina and optic nerve. Its flagship therapeutic, GB-102, is an injectable microparticle formulation of sunitinib administered directly into the eye. This compound is progressing through Phase I/IIa and IIb clinical trials for wet age-related macular degeneration, while also undergoing Phase IIa trials for diabetic macular edema. Furthermore, GB-102 is being explored as a treatment for diabetic retinopathy. The company's pipeline also includes GB-401, an intraocular implant designed to deliver a beta-adrenergic receptor inhibitor, intended for the management of primary open-angle glaucoma. Initially established as Graybug LLC in 2011, the firm rebranded to Graybug Vision, Inc. in 2016 and is headquartered in Redwood City, California.

Market snapshot

Symbol
GRAY
Price
$5.50
Day change
-10.80%
Market cap
$121.0M
P/E ratio
-4.22x
52-week range
4.88-20.3
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$27.83

Peer companies

  • aTyr Pharma, Inc. (ATYR)
  • Cyteir Therapeutics, Inc. (CYT)
  • Decibel Therapeutics, Inc. (DBTX)
  • Kinnate Biopharma Inc. (KNTE)
  • NGM Biopharmaceuticals, Inc. (NGM)
  • Paratek Pharmaceuticals, Inc. (PRTK)
  • Quoin Pharmaceuticals, Ltd. (QNRX)
  • RVL Pharmaceuticals plc (RVLP)

Recent insider activity

  • WILSON ROBERT N — P-Purchase (506 shares) on 2023-12-11
  • Leheny A. Rachel — P-Purchase (2000 shares) on 2023-11-07
  • Roberts Eric W — P-Purchase (2400 shares) on 2023-11-06
  • Roberts Eric W — P-Purchase (11249 shares) on 2023-11-03
  • Roberts Eric W — P-Purchase (3700 shares) on 2023-11-03

Open Graybug Vision, Inc. (GRAY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.